New drug duo tested in fight against rare, spreading eye cancer
NCT ID NCT05282901
Summary
This study is testing whether a combination of two existing cancer drugs, pembrolizumab and lenvatinib, can help control metastatic uveal melanoma, a rare and aggressive cancer that starts in the eye. It will enroll about 51 patients into two groups based on whether they have had a specific prior treatment. The main goal is to see if the drug combo can delay the cancer's progression and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 75005, France
Conditions
Explore the condition pages connected to this study.